Breast Cancer: Targets and Therapy

Antibody-Drug Conjugates for Breast Cancer Treatment

Antibody-drug conjugates (ADCs) consist of monoclonal antibodies linked to cytotoxic drugs, allowing for selective delivery of the therapeutic agent directly to cancer cells and minimizing damage to healthy tissues. Advances in ADC research have led to numerous approvals for clinical use, with significant impact on breast cancer therapy, as ADCs can effectively reduce tumor size and improve progression-free survival. With the ongoing identification of novel targets and indications, ADCs are poised to become a leader in the era of targeted therapies for breast cancer.